(1S,2S)-安非他酮N-1’-脱氧-beta-D-葡萄糖醛酸 | 23018-83-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (1S,2S)-安非他酮N-1’-脱氧-beta-D-葡萄糖醛酸
• 英文名称: D-glucuronic acid
• 英文别名: glucuronic acid；β-D-glucuronic acid；(2S,3S,4S,5R,6R)-3,4,5,6-tetrahydroxytetrahydropyran-2-carboxylic acid；β-D-glucopyranuronic acid；(2S,3S,4S,5R,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid
• CAS: 23018-83-9
• 化学式: C₆H₁₀O₇
• mdl: MFCD00077778
• 分子量: 194.141
• InChiKey: AEMOLEFTQBMNLQ-QIUUJYRFSA-N

物化性质

• 熔点：
  234-236 °C
• 沸点：
  495.2±45.0 °C(Predicted)
• 密度：
  1.987±0.06 g/cm3(Predicted)
• 溶解度：
  485 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  127
• 氢给体数：
  5
• 氢受体数：
  7

安全信息

• 储存条件：
  | 室温 |

反应信息

• 作为反应物：
  描述：

  (1S,2S)-安非他酮N-1’-脱氧-beta-D-葡萄糖醛酸 在 sodium ethoxide 作用下， 以 乙醇 为溶剂， 生成 β-D-glucuronic acid sodium salt
  参考文献：
  名称：

  Design, spectral characterization, anti-tumor and anti-inflammatory activity of triorganotin(IV) hydroxycarboxylates, apoptosis inducers: In vitro assessment of induction of apoptosis by enzyme, DNA-fragmentation, acridine orange and comet assays

  摘要：

  Interaction of triorganotin(IV) chlorides with sodium salt of hydroxycarboxylic acids results in the formation of triorganotin(IV) hydroxycarboxylates, R3Sn(L) [R = Me, n-Bu and Ph; L = anion of glucuronic (HGlu), gallic (HGal) and mandelic (HMal) acid]. They exhibit trigonal-bipyramidal geometry which is well supported by elemental analysis, IR, H-1, C-13, Sn-119 NMR and ESI-MS spectral data. Triorganotin(IV) hydroxycarboxylates have been screened in vitro against five cancer cell lines of human origin viz. MCF-7, HEK-293, PC-3, HCT-15 and HepG-2. Title complexes are found to be cytotoxic to mildly cytotoxic, and exhibited IC50 values in the range 4-30 mu g/mL. The results of enzyme assays viz. glutathione reductase, glutathione peroxidase, total glutathione content and lipid peroxidase assay on MCF-7 cells indicate that the reactive oxygen species generated in the cancer cells by triorganotin(IV) hydroxycarboxylates is responsible for cell death. Marginal increase of lactate dehydrogenase suggests that necrosis is also occurring to a small extent. DNA (deoxyribonucleic acid) fragmentation assay, acridine orange assay and comet assay clearly support that the cell death is mainly due to apoptosis. The results obtained for the in vivo anti-inflammatory activity (% inhibition) and toxicity (LD50 in mg/kg) suggested that the complexes have low toxicity and good anti-inflammatory activity. (C) 2014 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2014.02.034
• 作为产物：
  描述：

  nocardamin glucuronide 在 β-glucuronidase 作用下， 生成 (1S,2S)-安非他酮N-1’-脱氧-beta-D-葡萄糖醛酸
  参考文献：
  名称：

  诺卡明葡糖苷酸，一种从产阿斯卡霉素的菌株链霉菌中分离出来的铁氧胺铁载体的新成员。80H647。

  摘要：

  一种新的铁载体葡糖苷酸诺卡明葡糖苷酸 (1) 与诺卡明 (2) 一起通过将单株多化合物 (OSMAC) 方法应用于产阿斯卡霉素的菌株链霉菌属 (Streptomyces sp.) 进行分离。80H647，并使用质谱数据进行多变量分析。结构解析通过 NMR 和 MS 分析的组合完成。通过使用 β-葡萄糖醛酸酶水解、水解产物的后续衍生和与标准品比较，发现葡萄糖醛酸部分的绝对构型为 β-D-GlcA。1 的铁载体活性通过铬天青 S 测定进行评估，与 2 和去铁胺的活性相当（IC50 分别为 13.4、9.5 和 6.3 μM）。Nocardamin 葡糖苷酸 (1) 是铁载体葡糖苷酸的第一个例子。

  DOI：

  10.1038/s41429-019-0217-5

文献信息

• [EN] SULFINYLPYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] SULFINYLPYRIDINES ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：OBLIQUE THERAPEUTICS AB

  公开号：WO2018146468A1

  公开（公告）日：2018-08-16

  There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3, R4 and n have meanings provided in the description, which compounds are useful in the treatment of cancers.

  提供了式I（I）的化合物或其药用盐，其中L、R1、R2、R3、R4和n的含义如描述中所提供，这些化合物在治疗癌症方面是有用的。
• [EN] COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA SUBSTANCE AMYLOÏDE
  申请人：REMYND NV

  公开号：WO2016083490A1

  公开（公告）日：2016-06-02

  This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the novel compounds for use as a medicine, more in particular for the prevention or treatment of amyloid-related diseases, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such amyloid-related diseases. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  这项发明提供了式(I)或(II)或其立体异构体、对映异构体、消旋体或互变异构体的新化合物，其中取代基如规范中所定义。本发明还涉及用作药物的这些新化合物，更具体地用于预防或治疗与淀粉样蛋白相关的疾病，更具体地说是某些神经系统疾病，如被统称为tau病变的疾病，以及由细胞毒性α-突触核蛋白淀粉生成所特征化的疾病。本发明还涉及利用这些新化合物制备对治疗此类淀粉样蛋白相关疾病有用的药物。本发明还涉及包括这些新化合物的药物组合物以及这些新化合物的制备方法。
• [EN] DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK<br/>[FR] COMPOSÉS DE DIHYDROPYRROLONAPHTYRIDINONE COMME INHIBITEURS DE JAK
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010144486A1

  公开（公告）日：2010-12-16

  Disclosed are JAK inhibitors of formula (I) where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.

  揭示了式(I)的JAK抑制剂，其中G1、R1、R2、R3、R4、R5、R6和R7在规范中定义。还披露了含有这些化合物的药物组合物、试剂盒和制造物品，制备这些化合物的方法和材料，以及使用这些化合物治疗涉及免疫系统和炎症的疾病、紊乱和症状的方法，包括类风湿关节炎、血液恶性肿瘤、上皮癌（即癌症）和其他与JAK相关的疾病、紊乱或症状。
• [EN] PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES<br/>[FR] PRÉPARATION ET UTILISATIONS DE DÉRIVÉS PIÉGEURS D'ESPÈCES RÉACTIVES DE L'OXYGÈNE
  申请人：XW LAB INC

  公开号：WO2019033330A1

  公开（公告）日：2019-02-21

  Compounds of Formula (I) a or (I) b: including certain quinone derivatives, and the corresponding pharmaceutical compositions, which may serve to modulate ferroptosis in a subject. Also disclosed herein are the preparations of these compounds and pharmaceutical compositions and their potential uses in the manufacture of a medicament in reducing reactive oxygen species (ROS) in a cell and for preventing, treating, ameliorating certain related disorder or a disease.

  公式(I) a或(I) b的化合物：包括某些醌衍生物，以及相应的药物组合物，可以用于调节受试者中的铁死亡。本文还披露了这些化合物和药物组合物的制备方法，以及它们在制造药物中用于减少细胞中的活性氧化物（ROS）并预防、治疗、改善某些相关疾病或疾病的潜在用途。
• [EN] CYCLIC PHOSPHATE COMPOUNDS<br/>[FR] COMPOSÉS DE PHOSPHATE CYCLIQUE
  申请人：LIGAND PHARM INC

  公开号：WO2020219464A1

  公开（公告）日：2020-10-29

  Provided herein are cyclic phosphate compounds, their preparation and their uses, such as treating liver diseases or conditions or a disease or condition in which the physiological or pathogenic pathways involve the liver.

  本文提供了环磷酸酯化合物，它们的制备以及它们的用途，例如用于治疗肝脏疾病或病况，或者涉及肝脏的生理或病理途径的疾病或病况。